Neurodegeneration and Alzheimer's Disease : (Record no. 10142)
[ view plain ]
| 000 -LEADER | |
|---|---|
| fixed length control field | 11242nam a22005173i 4500 |
| 001 - CONTROL NUMBER | |
| control field | EBC5761264 |
| 003 - CONTROL NUMBER IDENTIFIER | |
| control field | MiAaPQ |
| 005 - DATE AND TIME OF LATEST TRANSACTION | |
| control field | 20240724113702.0 |
| 006 - FIXED-LENGTH DATA ELEMENTS--ADDITIONAL MATERIAL CHARACTERISTICS | |
| fixed length control field | m o d | |
| 007 - PHYSICAL DESCRIPTION FIXED FIELD--GENERAL INFORMATION | |
| fixed length control field | cr cnu|||||||| |
| 008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION | |
| fixed length control field | 240724s2019 xx o ||||0 eng d |
| 020 ## - INTERNATIONAL STANDARD BOOK NUMBER | |
| International Standard Book Number | 9781119356776 |
| Qualifying information | (electronic bk.) |
| 020 ## - INTERNATIONAL STANDARD BOOK NUMBER | |
| Canceled/invalid ISBN | 9781119356783 |
| 035 ## - SYSTEM CONTROL NUMBER | |
| System control number | (MiAaPQ)EBC5761264 |
| 035 ## - SYSTEM CONTROL NUMBER | |
| System control number | (Au-PeEL)EBL5761264 |
| 035 ## - SYSTEM CONTROL NUMBER | |
| System control number | (OCoLC)1099996770 |
| 040 ## - CATALOGING SOURCE | |
| Original cataloging agency | MiAaPQ |
| Language of cataloging | eng |
| Description conventions | rda |
| -- | pn |
| Transcribing agency | MiAaPQ |
| Modifying agency | MiAaPQ |
| 050 #4 - LIBRARY OF CONGRESS CALL NUMBER | |
| Classification number | RC365 .N487 2019 |
| 082 0# - DEWEY DECIMAL CLASSIFICATION NUMBER | |
| Classification number | 616.83110654 |
| 100 1# - MAIN ENTRY--PERSONAL NAME | |
| Personal name | Martins, Ralph N. |
| 245 10 - TITLE STATEMENT | |
| Title | Neurodegeneration and Alzheimer's Disease : |
| Remainder of title | The Role of Diabetes, Genetics, Hormones, and Lifestyle. |
| 250 ## - EDITION STATEMENT | |
| Edition statement | 1st ed. |
| 264 #1 - PRODUCTION, PUBLICATION, DISTRIBUTION, MANUFACTURE, AND COPYRIGHT NOTICE | |
| Place of production, publication, distribution, manufacture | Newark : |
| Name of producer, publisher, distributor, manufacturer | John Wiley & Sons, Incorporated, |
| Date of production, publication, distribution, manufacture, or copyright notice | 2019. |
| 264 #4 - PRODUCTION, PUBLICATION, DISTRIBUTION, MANUFACTURE, AND COPYRIGHT NOTICE | |
| Date of production, publication, distribution, manufacture, or copyright notice | ©2019. |
| 300 ## - PHYSICAL DESCRIPTION | |
| Extent | 1 online resource (543 pages) |
| 336 ## - CONTENT TYPE | |
| Content type term | text |
| Content type code | txt |
| Source | rdacontent |
| 337 ## - MEDIA TYPE | |
| Media type term | computer |
| Media type code | c |
| Source | rdamedia |
| 338 ## - CARRIER TYPE | |
| Carrier type term | online resource |
| Carrier type code | cr |
| Source | rdacarrier |
| 505 0# - FORMATTED CONTENTS NOTE | |
| Formatted contents note | Cover -- Title Page -- Copyright -- Contents -- List of Contributors -- Chapter 1 Current Understanding of Alzheimer's Disease and Other Neurodegenerative Diseases, and the Potential Role of Diet and Lifestyle in Reducing the Risks of Alzheimer's Disease and Cognitive Decline -- References -- Chapter 2 Alzheimer's Disease and Other Neurodegenerative Diseases -- 2.1 Introduction -- 2.2 Alzheimer's Disease -- 2.2.1 Pathology -- 2.2.2 Symptoms -- 2.2.3 Incidence -- 2.2.4 Onset and Risk Factors -- 2.2.5 Treatment -- 2.2.6 Potential for AD Prevention -- 2.3 Frontotemporal Lobe Dementia -- 2.3.1 Neuropathology and Causes -- 2.3.2 Treatment -- 2.3.3 Diagnosis and Clinical Overlap with Other Diseases -- 2.4 Vascular Dementia -- 2.4.1 Symptoms and Diagnosis -- 2.4.2 Causes and Risk Factors -- 2.4.3 Prevention and Treatment -- 2.4.4 Dementia with Lewy Bodies -- 2.4.5 Causes -- 2.4.6 Symptoms -- 2.4.7 Diagnosis of DLB -- 2.4.7.1 Clinical Approach to Dementias -- 2.5 Parkinson's Disease -- 2.5.1 Onset -- 2.5.2 Causes and Risk Factors -- 2.5.3 Incidence -- 2.5.4 Pathology -- 2.5.5 Treatment -- 2.6 Huntington's Disease -- 2.6.1 Genetics of the Disease -- 2.6.2 Incidence and Prevalence -- 2.6.3 Pathology -- 2.6.4 Treatment -- 2.7 Motor Neuron Diseases -- 2.7.1 Amyotrophic Lateral Sclerosis -- 2.7.2 Spinal Muscular Atrophy -- 2.7.3 Hereditary Spastic Paraplegia -- 2.7.4 Onset of MND and Differential Diagnosis -- 2.7.5 Incidence, Causes, and Risk Factors -- 2.7.6 Pathology -- 2.7.7 Treatment -- 2.8 Prion Diseases -- 2.8.1 Causes -- 2.8.2 Symptoms and Diagnosis -- 2.8.3 Treatment -- 2.8.4 Differential Diagnosis of the Various Types of Dementia -- 2.8.5 DLB Treatment -- 2.9 Summary -- References -- Chapter 3 Current and Developing Methods for Diagnosing Alzheimer's Disease -- 3.1 Introduction -- 3.2 Classical Post-Mortem Diagnosis -- 3.2.1 Plaques. |
| 505 8# - FORMATTED CONTENTS NOTE | |
| Formatted contents note | 3.2.2 Neurofibrillary Tangles (NFT) -- 3.2.3 Cerebral Amyloid Angiopathy (CAA) -- 3.2.4 Glial Responses -- 3.2.5 Brain Shrinkage -- 3.2.6 Loss of Synapses and Neurons -- 3.3 Clinical Diagnosis -- 3.3.1 Initial Assessment/Screening Tools -- 3.3.1.1 Mini‐Mental State Examination (MMSE) -- 3.3.1.2 Montreal Cognitive Assessment (MoCA) -- 3.3.1.3 Clinical Dementia Rating (CDR) -- 3.3.1.4 Clock Drawing -- 3.3.1.5 Seven‐Minute Screen -- 3.3.1.6 Alzheimer's Disease Assessment Scale (ADAS‐Cog) -- 3.3.1.7 Psychogeriatric Assessment Scales (PAS) -- 3.3.1.8 Dementia Rating Scale (DRS) -- 3.3.1.9 Mini‐Cog -- 3.3.1.10 Rowland Universal Dementia Assessment Scale (RUDAS) -- 3.3.1.11 The Consortium to Establish a Registry for Alzheimer's Disease (CERAD) Neuropsychological Battery (nb) and Other Tests -- 3.4 Brain Imaging in the Diagnosis of Alzheimer's Disease and Other Dementias -- 3.4.1 Imaging Tests in AD Diagnosis: Established Tests -- 3.4.1.1 Computed Tomography (CT) -- 3.4.1.2 Electroencephalography (EEG) -- 3.4.1.3 Magnetic Resonance Imaging (MRI), for the Assessment of Morphological Changes, and the Detection of Stroke -- 3.4.1.4 Positron Emission Tomography (PET) -- 3.4.1.5 FDG‐PET -- 3.4.2 Imaging Tests in AD Diagnosis: More Recently Developed Tests -- 3.4.2.1 MRI for Measuring Regional Blood Flow -- 3.4.2.2 Single Photon Emission Computed Tomography (SPECT) Scan -- 3.4.2.3 PiB‐PET -- 3.4.3 The Rapidly Evolving Diagnostic Criteria -- 3.4.4 CSF Biomarkers of AD -- 3.4.4.1 A& -- rmbeta -- , Tau, and A& -- rmbeta -- PP‐Related Biomarkers -- 3.4.4.2 Other Potential CSF Protein Biomarkers -- 3.4.4.3 Potential Lipid Biomarkers in the CSF -- 3.4.5 Blood Biomarkers of AD -- 3.4.5.1 A& -- rmbeta -- Peptides in Plasma -- 3.4.5.2 Other Potential Blood Biomarkers -- 3.4.5.3 Blood Proteins -- 3.4.6 Blood Lipids -- 3.4.7 Metabolites -- 3.4.8 Blood Platelets. |
| 505 8# - FORMATTED CONTENTS NOTE | |
| Formatted contents note | 3.4.9 Genetic Risk Factors -- 3.4.10 The Eye as a Window to the Brain -- 3.4.11 miRNA Tests -- 3.5 Conclusions -- References -- Chapter 4 The Link Between Diabetes, Glucose Control, and Alzheimer's Disease and Neurodegenerative Diseases -- 4.1 Introduction -- 4.2 The Impact of Type 2 Diabetes on the Brain -- 4.3 Evidence from Cell Culture, Animal, and Clinical Studies -- 4.3.1 CNS Insulin Signalling and Disruptions in AD -- 4.3.2 The Accumulation of A& -- rmbeta -- Is Associated with Impaired Insulin Signalling -- 4.3.3 Insulin Resistance Promotes the Accumulation of A& -- rmbeta -- -- 4.3.4 Impairments in Insulin Signalling Can Induce Hyperphosphorylation of Tau -- 4.3.5 Type 2 Diabetes and Neuroinflammation -- 4.3.6 Oxidative Stress and Mitochondrial Dysfunction in T2D and AD -- 4.3.7 Targeting Type 2 Diabetes to Slow Down Progression/Prevent Neurodegeneration and Cognitive Decline -- 4.4 Conclusions -- References -- Chapter 5 Diet and Nutrition, and their Influence on Alzheimer's Disease and other Neurodegenerative Diseases -- 5.1 Introduction -- 5.2 Dietary Patterns -- 5.3 Key Macronutrients -- 5.3.1 Dietary Fatty Acids -- 5.3.2 Cholesterol -- 5.3.3 Polyunsaturated Fatty Acids -- 5.3.4 Dietary Carbohydrates -- 5.4 Key Micronutrients -- 5.4.1 Water Soluble Vitamins -- 5.4.1.1 B Vitamins -- 5.4.2 Fat Soluble Vitamins -- 5.4.2.1 Vitamin A (Retinol, Retinal, and Retinoic Acid) -- 5.4.2.2 Vitamin D -- 5.4.2.3 Vitamin E -- 5.4.3 Dietary Minerals -- 5.4.3.1 Selenium -- 5.4.3.2 Manganese -- 5.4.3.3 Zinc, Iron, Copper, and Calcium -- 5.5 Conclusion -- References -- Chapter 6 Carbohydrate and Protein Metabolism: Influences on Cognition and Alzheimer's Disease -- 6.1 Carbohydrates -- 6.1.1 Carbohydrate Digestion -- 6.1.2 Glucose Ingestion and Use -- 6.1.3 Glucose and Insulin, Insulin Resistance, and Type 2 Diabetes (Short Summary). |
| 505 8# - FORMATTED CONTENTS NOTE | |
| Formatted contents note | 6.1.4 Relative Intake of Carbohydrate and its Impacts on Neurodegenerative Disease Risk -- 6.1.5 Ketogenic Diets -- 6.1.6 Glucose and Its Effects on Cognition -- 6.1.7 Possible Mechanisms Related to Memory Enhancement with Glucose -- 6.1.7.1 Glucose and the Hippocampus -- 6.1.7.2 Glucose Availability in Brain Cells -- 6.1.7.3 Glucose and the Central Cholinergic System -- 6.1.7.4 ATP‐Regulated Potassium (K‐ATP) Channels and Brain Control of Glucose Homeostasis -- 6.1.7.5 Effects of High Fructose Diets -- 6.1.7.6 Sucrose -- 6.2 Proteins -- 6.2.1 Protein Metabolism in General -- 6.2.2 Links Between Specific Amino Acids and Brain Function -- 6.2.2.1 Tryptophan -- 6.2.2.2 Tyrosine -- 6.2.3 Clinical Studies of Protein Supplementation -- 6.2.4 Links Between Loss of Protein Function and Neurodegeneration -- 6.2.5 Clearance Mechanisms Associated with Proteinopathies Involved in Neurodegeneration -- 6.2.6 Role of Protein Crosslinking and Inflammation in Neurodegeneration and AD -- 6.3 Conclusion -- References -- Chapter 7 Fat and Lipid Metabolism and the Involvement of Apolipoprotein E in Alzheimer's Disease -- 7.1 Introduction -- 7.2 Alzheimer's Disease -- 7.3 Cholesterol and Lipid Metabolism -- 7.3.1 Cholesterol Synthesis and Metabolism -- 7.3.2 Oxysterols -- 7.3.2.1 Oxysterols in AD -- 7.3.3 Pathways of Dietary (Exogenous) Lipid Homeostasis -- 7.3.4 Pathways of Endogenous Lipid Homeostasis -- 7.3.5 Peripheral Clearance of Lipoproteins and Reverse Cholesterol Transport -- 7.3.5.1 Lipoproteins in the CNS -- 7.4 Apolipoprotein E Alleles and Isoforms -- 7.4.1 ApoE in the Brain -- 7.4.2 Apolipoprotein E and Alzheimer's Disease -- 7.4.2.1 ApoE Binding to A& -- rmbeta -- -- 7.4.2.2 ApoE in the Cellular Clearance of A& -- rmbeta -- -- 7.4.2.3 ApoE and Antioxidant Properties -- 7.4.2.4 ApoE and Tissue Transglutaminase. |
| 505 8# - FORMATTED CONTENTS NOTE | |
| Formatted contents note | 7.4.2.5 Apolipoprotein J (Clusterin, CLU) -- 7.5 LRP‐1 in the Brain and Its Role in A& -- rmbeta -- Clearance -- 7.5.1 LDL, HDL, and AD -- 7.5.2 Statins, Cholesterol, and AD -- 7.6 The Role of Lipid Rafts in Neurodegenerative Diseases -- 7.7 Changes to Glycerophospholipids in Alzheimer's Disease -- 7.7.1 Omega‐3 and Omega‐6 Fatty Acids -- 7.7.1.1 Omega‐3 Fatty Acids, Modern Diets, and Health Implications -- 7.8 Sphingolipids -- 7.8.1 Ceramides -- 7.8.2 Sulfatides -- 7.8.3 Gangliosides -- 7.9 Conclusions -- References -- Chapter 8 Inflammation in Alzheimer's Disease, and Prevention with Antioxidants and Phenolic Compounds - What Are the Most Promising Candidates? -- 8.1 Introduction -- 8.2 Inflammation and the Immune Response in AD -- 8.2.1 The Role of Microglia and Astrocytes in Chronic Inflammation in AD -- 8.3 Oxidative Stress -- 8.3.1 Advanced Glycation End Products -- 8.3.2 Involvement of the Complement System in AD -- 8.3.3 Involvement of Cytokines and Chemokines in Inflammation -- 8.3.4 Inflammation - Susceptibility to A& -- rmbeta -- Deposition or Aggregation -- 8.3.5 Inflammation Can Influence A< -- ?Undefined ?> -- PP Metabolism and A& -- rmbeta -- Clearance Directly -- 8.4 Current Medications for AD -- 8.4.1 Current Medications - Acetylcholinesterase Inhibitors and Memantine -- 8.5 Disease Modification and Treatment Approaches -- 8.5.1 Non‐Steroidal Anti‐Inflammatory Drugs (NSAID) -- 8.6 Some Anti‐inflammatory Foods, Supplements, and Newly Developed Drugs for the Treatment of AD -- 8.6.1 Cinnamon/Cinnamaldehyde -- 8.6.2 (-)Epigallocatechin‐3‐Gallate (EGCG) and Other Green Tea Polyphenols -- 8.6.3 Curcumin -- 8.6.4 Other Polyphenolic Antioxidants -- 8.6.5 Omega‐3 (n‐3) Essential Fatty Acids -- 8.6.6 Lipoic Acid -- 8.7 Conclusion -- References. |
| 505 8# - FORMATTED CONTENTS NOTE | |
| Formatted contents note | Chapter 9 Cognitive Impairments in Alzheimer's Disease and Other Neurodegenerative Diseases. |
| 588 ## - SOURCE OF DESCRIPTION NOTE | |
| Source of description note | Description based on publisher supplied metadata and other sources. |
| 590 ## - LOCAL NOTE (RLIN) | |
| Local note | Electronic reproduction. Ann Arbor, Michigan : ProQuest Ebook Central, 2024. Available via World Wide Web. Access may be limited to ProQuest Ebook Central affiliated libraries. |
| 650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | Nervous system-Degeneration. |
| 655 #4 - INDEX TERM--GENRE/FORM | |
| Genre/form data or focus term | Electronic books. |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Brennan, Charles S. |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Fernando, Binosha. |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Brennan, Margaret A. |
| 700 1# - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Fuller, Stephanie J. |
| 776 08 - ADDITIONAL PHYSICAL FORM ENTRY | |
| Relationship information | Print version: |
| Main entry heading | Martins, Ralph N. |
| Title | Neurodegeneration and Alzheimer's Disease |
| Place, publisher, and date of publication | Newark : John Wiley & Sons, Incorporated,c2019 |
| International Standard Book Number | 9781119356783 |
| 797 2# - LOCAL ADDED ENTRY--CORPORATE NAME (RLIN) | |
| Corporate name or jurisdiction name as entry element | ProQuest (Firm) |
| 856 40 - ELECTRONIC LOCATION AND ACCESS | |
| Uniform Resource Identifier | <a href="https://ebookcentral.proquest.com/lib/orpp/detail.action?docID=5761264">https://ebookcentral.proquest.com/lib/orpp/detail.action?docID=5761264</a> |
| Public note | Click to View |
No items available.